抄録
Objective: To present clinical experience with the anti-anxiety drug, Solanax®, in the treatment of 17 glossodynia patients.
Study design: The patients consisted of 1 male and 16 females, 17 in total, with amean age of 67.9 ± 2.4 years, and CMI testing was performed. Solanax®; was administered orally to each of the 17 patients for 12 weeks. The clinical examination evaluated oral stimulatory, neuropsychological and somatic symptoms.
Results: In the CMI test, 19%(3/16) of patients were diagnosed as either provisionally neurotic or neurotic. Tongue pain recovery rates were high after 12 weeks of Solanax ® administration and 2 and 4 weeks after its completion, with a reduction of symptoms in more than 60% of the patients. The recovery rates for other oral stimulatory symptoms besides tongue pain were also high after 12 weeks of administration and 2 and 4 weeks after its completion, with improvement observed in more than 55% of cases. There were, however, as side effects, reports of drowsiness (12%: 2/17), unsteadiness on the feet (6%: 1/17) and dry mouth (6%: 1/17).
Conclusion: The results suggest that Solanax® may be clinically useful and safe for the long-term treatment of glossodynia patients.
